Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. - Spitzer,M.S.; Yoeruek,E.; Sierra,A. (Graefes Arch Clin Exp Ophthalmol, 2007)